Biome Australia Launches Major Clinical Trial for Proprietary Probiotic BMB18

Ethics Approval Clears Path for Clinical Trial

Biome Australia Limited (ASX – BIO) has reached a significant milestone with the La Trobe University Human Research Ethics Committee granting approval for its first human clinical trial of the proprietary probiotic strain Lactobacillus plantarum BMB18 (DSM 35214). This approval removes the final regulatory hurdle, allowing the company to commence recruitment of 240 participants in February 2026 as planned.

Trial Design and Objectives

The upcoming trial is a randomised, double-blind, placebo-controlled study designed to rigorously assess the efficacy of BMB18 in adults experiencing digestive discomfort such as bloating, alongside occasional sleep and mood disturbances. Participants will be assigned to two active dosage levels or placebo, enabling Biome to explore multiple therapeutic applications and dosage strategies. The 12-month study is budgeted at approximately $140,000 and will be managed within Biome’s existing research and development framework.

Building on Strong Preclinical Foundations

This clinical trial follows promising in vitro research demonstrating BMB18’s capacity to modulate immune responses, reduce inflammation and oxidative stress, and maintain intestinal barrier integrity. These findings underpin the rationale for investigating its potential benefits in human subjects, particularly in areas of gut health, mood regulation, and sleep quality.

Strategic Importance of Proprietary IP

BMB18 is a wholly owned asset of Biome, registered with the German culture bank DSMZ, which secures its intellectual property rights internationally. This ownership not only protects Biome’s competitive position but also opens avenues for future licensing and product innovation. Clinical validation of BMB18 is expected to enhance Biome’s Activated Probiotics and Activated Therapeutics ranges, supporting growth in its largest volume category, gut health.

Company Vision and Market Implications

Biome’s Managing Director and Founder, Blair Vega Norfolk, emphasised the strategic value of BMB18, describing it as one of the company’s most significant assets. The clinical trial aligns with Biome’s Vision 27 strategic plan, focusing on proprietary strain development and commercialisation. Successful outcomes could strengthen Biome’s market position by enabling new product launches with robust IP protection and potential licensing deals, thereby enhancing long-term shareholder value.